Reimbursed Care Access in Guam

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Guam’s Uniform Controlled Substances Act adopts and mirrors federal scheduling unless locally re‑scheduled, and federal Schedule I placement for psilocybin means possession, manufacture, or distribution is prohibited outside of DEA/IRB‑approved research. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA remains Schedule I at the federal level unless and until a re‑scheduling or FDA approval pathway completes; access in Guam would therefore be limited to properly authorized investigational trials. # #

Esketamine nasal spray (Spravato) is an FDA‑approved medication for specific depressive indications and is supplied under a REMS program that requires administration in certified clinical settings; Guam providers may administer it in REMS‑certified clinics subject to local licensure and payer rules. The original NDA and REMS documentation identify Spravato as an FDA‑approved product; Janssen’s labeling and FDA application records document the approval and REMS requirements. # #

Regulatory bodies and clinical operations: In Guam the Department of Public Health and Social Services (DPHSS) administers controlled‑substance scheduling and must publish rules for local dispensing; because Guam’s statute provides that a substance designated or rescheduled under Federal law will be treated similarly within 30 days, federal FDA/DEA determinations effectively govern local legal medical availability for esketamine. Clinics in Guam wishing to offer Spravato must comply with the FDA REMS program (certified site, staff training, observation period) and with Guam licensing for outpatient clinics. #

Reimbursement and payer coverage: Federally, Medicaid programs are required to operate within the Medicaid Drug Rebate Program and states/territories generally cover FDA‑approved covered outpatient drugs if manufacturer rebate agreements are in place, but prior authorization and utilization controls are commonly applied; as a result, coverage for Spravato is available in many Medicaid/Medicare/private plans but is implemented with variable prior‑authorization criteria, medical necessity requirements (e.g., documented treatment‑resistant depression, failed trials of oral antidepressants), and site‑of‑care restrictions. Guam’s Medicaid and commercial insurers will therefore determine coverage and prior authorization locally; the federal statute governing coverage conditions and state discretion for prior authorization is 42 U.S.C. § 1396r‑8. # #

Clinical indications and documentation: Payers typically require documentation of Major Depressive Disorder with treatment‑resistant features (examples: inadequate response to ≥2 adequate oral antidepressant trials), psychiatrist evaluation, REMS‑certified administration, and follow‑up/monitoring documentation. Guam providers should expect prior authorization and to submit the same types of supporting records commonly required in U.S. states (diagnostic codes, history of failed therapies, treatment plan). Regional nuances: Guam follows federal law for scheduling and will adopt FDA/DEA determinations rapidly; reimbursement specifics depend on Guam Medicaid’s fee schedule / MCO policies and on whether the manufacturer participates in rebate programs affecting territorial coverage. # #

Ketamine (racemic ketamine) is a federally controlled Schedule III medication with accepted medical uses (anesthesia) and is commonly used off‑label in the U.S. for treatment‑resistant depression via IV/IM/oral protocols—clinical provision is legal when prescribed and administered by licensed clinicians, but coverage and reimbursement are inconsistent and typically limited. The DEA scheduling and clinical use as an anesthetic are established federal facts; off‑label psychiatric use remains outside FDA‑labeled psychiatric indications. # #

Clinical/regulatory context in Guam: Guam’s Uniform Controlled Substances Act treats substances consistent with federal scheduling and allows DPHSS to adopt rules; therefore ketamine may be possessed and administered by licensed medical facilities in Guam for authorized medical purposes (e.g., anesthesia) and may be used off‑label for psychiatric indications at clinician discretion. However, because off‑label use is not an FDA‑labeled indication, payer coverage (Medicaid/Medicare/private) is uncertain and often requires case‑by‑case review or is explicitly excluded. #

Reimbursement and access: Insurers and Medicaid programs commonly establish more restrictive coverage for off‑label ketamine infusions than for FDA‑approved esketamine (Spravato). Across U.S. jurisdictions, Spravato is more frequently reimbursed under formal policies with prior authorization, while IV ketamine for depression is frequently billed as an experimental/off‑label service and often remains self‑pay unless a specific state/plan policy allows coverage. Guam patients should expect that private clinics may offer IV ketamine on a self‑pay basis, and that obtaining reimbursement will generally require prior authorization and strong medical necessity documentation; local Guam Medicaid or any MCOs serving Guam beneficiaries set final reimbursement rules per federal/state frameworks. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (N,N‑Dimethyltryptamine) is Schedule I at the federal level and therefore not authorized for general medical use in Guam except within DEA/IRB‑approved trials. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT is treated as a controlled Schedule I compound in U.S. federal listings and therefore access in Guam is limited to properly authorized clinical research contexts. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is not an FDA‑approved therapeutic and is generally controlled or excluded from medical practice in U.S. jurisdictions; access in Guam would be limited to approved investigational settings. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Components of ayahuasca (notably DMT) are Schedule I federally, so traditional sacramental use would not be legally authorized in Guam absent special religious exemptions or controlled research approvals. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (a phenethylamine found in peyote and other cacti) is Schedule I federally except for narrow, recognized Native American Church exemptions under U.S. federal law; Guam does not provide general medical access outside of research. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The 2C‑family and many substituted phenethylamines are treated as controlled/analog compounds under federal law and therefore are prohibited in Guam except in properly authorized research. # #